Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ Vaccine Safety: Germany Introduces Age Restrictions, But EMA Says Rare Blood Clot Link Still Unproven

Canada Also Imposes Age Restrictions

Executive Summary

The European Medicines Agency will reach its scientific conclusion next week, but countries are already moving to restrict use of the vaccine.

You may also be interested in...

EMA Expected To Confirm AZ Vaccine Link To Rare Blood Clot

Growing evidence of an association between the vaccine and rare, sometimes fatal blood clots puts Europe’s vaccine program leaders in a difficult position.

Work Underway To Demystify Why Regulators Respond Differently To Drug Safety Issues

An independent UK-based pharmacovigilance unit has begun exploring and analyzing why national regulatory authorities across the globe respond differently to the same post-marketing concerns. 

After Vaccine Recalculation, AstraZeneca Looks To Move On But Likely Faces Extra US FDA Scrutiny

Results for AstraZeneca’s COVID shot edge down to 76% after data and safety monitoring board raised alarm about outdated figures.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts